BACKGROUND: Despite widespread dissatisfaction and low treatment persistence in moderate to severe psoriasis, patients' reasons behind treatment discontinuation remain poorly understood. OBJECTIVES: We sought to characterize patient-reported reasons for discontinuing commonly used treatments for moderate to severe psoriasis in real-world clinical practice. METHODS: A total of 1095 patients with moderate to severe plaque psoriasis from 10 dermatology practices who received systemic treatments completed a structured interview. Eleven reasons for treatment discontinuation were assessed for all past treatments. RESULTS: A total of 2231 past treatments were reported. Median treatment duration varied by treatment, ranging from 6.0 to 20.5 months (P < .001). The frequency of each cited discontinuation reasons differed by treatment (all P < .01). Patients who received etanercept (odds ratio [OR] 5.19; 95% confidence interval [CI] 3.23-8.33) and adalimumab (OR 2.10; 95% CI 1.20-3.67) were more likely to cite a loss of efficacy than those who received methotrexate. Patients who received etanercept (OR 0.34; 95% CI 0.23-0.49), adalimumab (OR 0.48; 95% CI 0.30-0.75), and ultraviolet B phototherapy (OR 0.21; 95% CI 0.14-0.31) were less likely to cite side effects than those who received methotrexate, whereas those who received acitretin (OR 1.56; 95% CI 1.08-2.25) were more likely to do so. Patients who underwent ultraviolet B phototherapy were more likely to cite an inability to afford treatment (OR 7.03; 95% CI 3.14-15.72). LIMITATIONS: The study is limited by its reliance on patient recall. CONCLUSIONS: Different patterns of treatment discontinuation reasons are important to consider when developing public policy and evidence-based treatment approaches to improve successful long-term psoriasis control.
BACKGROUND: Despite widespread dissatisfaction and low treatment persistence in moderate to severe psoriasis, patients' reasons behind treatment discontinuation remain poorly understood. OBJECTIVES: We sought to characterize patient-reported reasons for discontinuing commonly used treatments for moderate to severe psoriasis in real-world clinical practice. METHODS: A total of 1095 patients with moderate to severe plaque psoriasis from 10 dermatology practices who received systemic treatments completed a structured interview. Eleven reasons for treatment discontinuation were assessed for all past treatments. RESULTS: A total of 2231 past treatments were reported. Median treatment duration varied by treatment, ranging from 6.0 to 20.5 months (P < .001). The frequency of each cited discontinuation reasons differed by treatment (all P < .01). Patients who received etanercept (odds ratio [OR] 5.19; 95% confidence interval [CI] 3.23-8.33) and adalimumab (OR 2.10; 95% CI 1.20-3.67) were more likely to cite a loss of efficacy than those who received methotrexate. Patients who received etanercept (OR 0.34; 95% CI 0.23-0.49), adalimumab (OR 0.48; 95% CI 0.30-0.75), and ultraviolet B phototherapy (OR 0.21; 95% CI 0.14-0.31) were less likely to cite side effects than those who received methotrexate, whereas those who received acitretin (OR 1.56; 95% CI 1.08-2.25) were more likely to do so. Patients who underwent ultraviolet B phototherapy were more likely to cite an inability to afford treatment (OR 7.03; 95% CI 3.14-15.72). LIMITATIONS: The study is limited by its reliance on patient recall. CONCLUSIONS: Different patterns of treatment discontinuation reasons are important to consider when developing public policy and evidence-based treatment approaches to improve successful long-term psoriasis control.
Authors: Andrea W Evers; Marloes M Kleinpenning; Tim Smits; Jan Boezeman; Peter C van de Kerkhof; Floris W Kraaimaat; Marie-Jeanne P Gerritsen Journal: Arch Dermatol Date: 2010-02
Authors: Joel M Gelfand; Andrea L Neimann; Daniel B Shin; Xingmei Wang; David J Margolis; Andrea B Troxel Journal: JAMA Date: 2006-10-11 Impact factor: 56.272
Authors: Lidian L A Lecluse; Rieke J B Driessen; Phyllis I Spuls; Elke M G J de Jong; Steven O Stapel; Martijn B A van Doorn; Jan D Bos; Gert-Jan Wolbink Journal: Arch Dermatol Date: 2010-02
Authors: Brad A Yentzer; Christopher B Yelverton; Gregory L Simpson; Jason F Simpson; Wenke Hwang; Rajesh Balkrishnan; Steven R Feldman Journal: Dermatol Online J Date: 2009-04-15
Authors: Alexa B Kimball; Dafna Gladman; Joel M Gelfand; Kenneth Gordon; Elizabeth J Horn; Neil J Korman; Gretchen Korver; Gerald G Krueger; Bruce E Strober; Mark G Lebwohl Journal: J Am Acad Dermatol Date: 2008-03-04 Impact factor: 11.527
Authors: Ladan Afifi; Lindsey Shankle; April W Armstrong; Marc Boas; Alisha Bridges; Vivian Chiguil; Frank Doris; Kristina Callis Duffin; Eric Fielding; Roy Fleischmann; Joel M Gelfand; Matthew Kiselica; Catherine Kiselica; Brian LaFoy; John J Latella; Junko Takeshita; Sarah Truman; Marilyn T Wan; Vickie Wilkerson; Jashin J Wu; Michael P Siegel; Wilson Liao Journal: J Psoriasis Psoriatic Arthritis Date: 2017
Authors: Joel M Gelfand; Shuwei Wang; Junko Takeshita; Andrew D Robertson; Gerald G Krueger; Kristina Callis Duffin; Abby S Van Voorhees Journal: JAMA Dermatol Date: 2013-04 Impact factor: 10.282
Authors: Benjamin H Kaffenberger; Grace L Lee; Kelly Tyler; Derek V Chan; Wael Jarjour; Maria E Ariza; Marshall V Williams; Henry K Wong Journal: Hum Vaccin Immunother Date: 2014-02-03 Impact factor: 3.452
Authors: Jalpa A Doshi; Junko Takeshita; Lionel Pinto; Penxiang Li; Xinyan Yu; Preethi Rao; Hema N Viswanathan; Joel M Gelfand Journal: J Am Acad Dermatol Date: 2016-03-04 Impact factor: 11.527
Authors: K Callis Duffin; H Yeung; J Takeshita; G G Krueger; A D Robertson; A B Troxel; D B Shin; A S Van Voorhees; J M Gelfand Journal: Br J Dermatol Date: 2014-03 Impact factor: 9.302
Authors: D Timerman; P M Devlin; V E Nambudiri; N A Wright; R A Vleugels; R A Clark; T S Kupper; J F Merola; M Patel Journal: Clin Exp Dermatol Date: 2016-02-05 Impact factor: 3.470